23-Aug-15 Emerging-market sales for the big pharmaceuticals firms increased by about 5.5% year over year in the second quarter, well below the 9% average of the prior four quarters. Macroeconomic pressures are increasing. Weaker currencies hurt sales, a factor put into clear focus by China’s devaluation of the yuan. [image: Nai 500]

26-Aug-15 China is aiming to control “wildly” growing stem cell therapy, issuing its first regulation covering the largely controversial medical procedure. “Only eligible hospitals can work with stem cells in clinical trials for research and there must not be fees or advertising,” said the National Health and Family Planning Commission. [image: Liu Haifeng / Xinhua Press / Corbis]

19-Aug-15 A new guideline allows foreign drugs to undergo clinical trials in their home country and in China at the same pace, speeding up approval procedures for new drugs that are badly needed in China. Clinical trials of new foreign drugs in China normally lag behind those in the home country. [image: Alamy / Daily Mail]

14-Aug-15 China's medical technology sector growth exceeds the global average, but medical technology imports are declining as foreign investors are hampered by "buy local" guidelines and murky registration criteria. Local producers are under pressure to modernise and the government is funding innovation. [image: PolyOne]

13-Aug-15 With a view to further expanding its pan-Asia presence, Singapore's Fullerton Healthcare recently inked a deal to acquire a majority stake in HMMP Limited, a medical network based in Hong Kong. The acquisition will help Fullerton in its mission to transform healthcare standards across Asia, and make it more accessible and affordable, the company said. [image: Fullerton Healthcare]